The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Rouse had presented with symptoms including intense swelling in her legs that she originally thought could be linked to her ...

Learn more about whether Riot Platforms, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...